Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
The present study was designed to investigate the anticoagulant action of inhaled low-molecular-weight (LMW) heparin on the release of tissue factor pathway inhibitor (TFPI) and on antifactor Xa activity, Heptest, activated partial thromboplastin time (APTT) and thrombin clotting time (TCT) in healthy volunteers. 3000 IU (group 1), 9000 IU (group 2), 27,000 IU (group 3) or 54,000 IU (group 4) LMW-heparin were given to 20 healthy volunteers each at 4 weeks intervals by inhalation. For safety reasons a dose escalating design was chosen. APTT and TCT did not change after inhalation of any dose of LMW-heparin as well as all parameters in group 1. In group 2, Heptest coagulation times were prolonged from 18.7 +/- 2.0 s before to 26.1 +/- 5.2 s 6 h and 20.5 +/- 1.9 s 24 h after inhalation and the other parameters remained uneffected. In group 3, S2222 method and the protamine assay increased from 0.01 to about 0.1 IU/ml 6 h after inhalation and returned to normal values after 24 h. TFPI antigen increased from 74.1 +/- 13.9 to 80.5 +/- 14.2 ng/ml 3 h after inhalation. TFPI activity remained unchanged. Heptest coagulation values were prolonged to 42 +/- 7.6 s after 6 h and returned to normal within 72 h after inhalation. In group 4, the following changes were observed: antifactor Xa activity increased to 0.343 +/- 0.196 U/ml after 6 h and normalized after 72 h. The protamine assay detected 0.2 +/- 0.18 U LMWH/ml after 6 h, TFPI antigen increased to 103 +/- 17.9 ng/ml and TFPI activity to 1.14 +/- 0.23 U 3 h after inhalation. All tests were normal after 24 h. Heptest coagulation values increased to 77.5 +/- 11.8 s 6 h after inhalation and normalized after 144 h. The area under the activity time curve of the S2222 method and of the Heptest assay increased with increasing doses (r = 0.677 and r = 0.571), respectively. The calculated elimination half-life of the aXa-effect was 7.5 h using S2222-, Heptest- and protamine assays. The data demonstrate a resorption of LMW-heparin by intrapulmonary route in man. The dose to produce antifactor Xa levels, prolongations of Heptest coagulation values and in releasing TFPI is about ten-fold higher than after subcutaneous administration.
Harenberg
J
J
1st Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Klinikum Mannheim, Germany.
Malsch
R
R
Angelescu
M
M
Lange
C
C
Michaelis
H C
HC
Wolf
H
H
Heene
D L
DL
D000280:Administration, Inhalation; D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology*; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008168:Lung / Q000187:drug effects*; D008970:Molecular Weight; D010314:Partial Thromboplastin Time; D011479:Protamines; D013918:Thrombin Time; D013925:Thromboplastin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D008074:Lipoproteins; D011479:Protamines; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin; D013925:Thromboplastin